Neutrophil CD64 expression levels in IGRA-positive individuals distinguish latent tuberculosis from active disease.
Journal
Memorias do Instituto Oswaldo Cruz
ISSN: 1678-8060
Titre abrégé: Mem Inst Oswaldo Cruz
Pays: Brazil
ID NLM: 7502619
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
12
2018
accepted:
22
02
2019
entrez:
11
4
2019
pubmed:
11
4
2019
medline:
6
6
2019
Statut:
ppublish
Résumé
CD64 (FcγR1) is a high-affinity receptor for monomeric IgG1 and IgG3. Circulating neutrophils express very low amounts of CD64 on their surface. Our primary aim was to investigate the utility of neutrophil CD64 surface expression as a biomarker of active pulmonary tuberculosis (TB). We hypothesised that elevated neutrophil CD64 expression in TB infection would be associated with interferon gamma (IFN-γ) as an inducer of CD64 expression. The expression level of CD64 per neutrophil (PMN CD64 index) was quantitatively measured with flow cytometry using a Leuko64 kit in samples from patients with TB and latent TB infection (LTBI) as well as healthy controls, as part of a prospective cohort study in Brazil. The PMN CD64 index in patients with TB was higher than that in healthy controls and LTBI. Receiver operating characteristic curve analyses determined that the PMN CD64 index could discriminate patients with TB from those with LTBI and healthy individuals. PMN CD64 index levels returned to baseline levels after treatment. The positive regulation of CD64 expression in circulating neutrophils of patients with active TB could represent an additional biomarker for diagnosis of active TB and could be used for monitoring individuals with LTBI before progression of TB disease.
Sections du résumé
BACKGROUND
BACKGROUND
CD64 (FcγR1) is a high-affinity receptor for monomeric IgG1 and IgG3. Circulating neutrophils express very low amounts of CD64 on their surface.
OBJECTIVES
OBJECTIVE
Our primary aim was to investigate the utility of neutrophil CD64 surface expression as a biomarker of active pulmonary tuberculosis (TB). We hypothesised that elevated neutrophil CD64 expression in TB infection would be associated with interferon gamma (IFN-γ) as an inducer of CD64 expression.
METHODS
METHODS
The expression level of CD64 per neutrophil (PMN CD64 index) was quantitatively measured with flow cytometry using a Leuko64 kit in samples from patients with TB and latent TB infection (LTBI) as well as healthy controls, as part of a prospective cohort study in Brazil.
FINDINGS
RESULTS
The PMN CD64 index in patients with TB was higher than that in healthy controls and LTBI. Receiver operating characteristic curve analyses determined that the PMN CD64 index could discriminate patients with TB from those with LTBI and healthy individuals. PMN CD64 index levels returned to baseline levels after treatment.
CONCLUSIONS
CONCLUSIONS
The positive regulation of CD64 expression in circulating neutrophils of patients with active TB could represent an additional biomarker for diagnosis of active TB and could be used for monitoring individuals with LTBI before progression of TB disease.
Identifiants
pubmed: 30970080
pii: S0074-02762019000100319
doi: 10.1590/0074-02760180579
pmc: PMC6454854
pii:
doi:
Substances chimiques
Biomarkers
0
FCGR1A protein, human
0
Receptors, IgG
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e180579Références
Nature. 2001 Jan 11;409(6817):198-201
pubmed: 11196644
Clin Microbiol Infect. 2005 Sep;11(9):730-5
pubmed: 16104988
Acta Biochim Pol. 2006;53(2):257-68
pubmed: 16770444
J Rheumatol. 2006 Dec;33(12):2416-24
pubmed: 17080517
J Mol Med (Berl). 2007 Jun;85(6):613-21
pubmed: 17318616
Cytokine. 2006 Dec;36(5-6):283-90
pubmed: 17368039
Eur J Immunol. 2007 Jun;37(6):1594-9
pubmed: 17474153
Mediators Inflamm. 2008;2008:202646
pubmed: 18604302
Blood. 2009 Jan 22;113(4):887-92
pubmed: 18849484
Eur Respir J. 2009 May;33(5):956-73
pubmed: 19407047
Public Health Rep. 2009 May-Jun;124(3):471-4
pubmed: 19445426
BMC Biol. 2010 Jul 01;8:84
pubmed: 20619006
Nature. 2010 Aug 19;466(7309):973-7
pubmed: 20725040
Eur J Immunol. 2011 Jul;41(7):1941-7
pubmed: 21509782
Eur J Immunol. 2012 Nov;42(11):2925-36
pubmed: 22851198
PLoS One. 2013 May 14;8(5):e64215
pubmed: 23691171
Clin Microbiol Rev. 2014 Jan;27(1):3-20
pubmed: 24396134
Mod Rheumatol. 2014 Sep;24(5):770-4
pubmed: 24471997
J Immunol. 1989 Oct 1;143(7):2295-301
pubmed: 2476506
Am J Med Sci. 2015 Nov;350(5):387-92
pubmed: 26379042
PLoS Negl Trop Dis. 2016 Aug 24;10(8):e0004955
pubmed: 27556927
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Lancet Respir Med. 2017 Apr;5(4):259-268
pubmed: 28159608
PLoS One. 2017 Feb 16;12(2):e0171358
pubmed: 28208160
PLoS Negl Trop Dis. 2017 Mar 29;11(3):e0005486
pubmed: 28355218
Nat Commun. 2017 Jul 03;8:15949
pubmed: 28671185
J Leukoc Biol. 2018 May;103(5):829-838
pubmed: 29462505
Immunol Today. 1988 Jul-Aug;9(7-8):185-7
pubmed: 3255342
J Med Microbiol. 1996 Feb;44(2):135-40
pubmed: 8642575